Reda Bouabdallah

Marseille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 126 publications

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.

Journal: British journal of haematology

Published: December 03, 2024

Tell-tale immune-related neurological syndromes: Should we look for and underlying low-grade B-cell lymphoma? A retrospective study on 12 cases.

Tell-tale immune-related neurological syndromes: Should we look for and underlying low-grade B-cell lymphoma? A retrospective study on 12 cases.

Journal: Pathology, research and practice

Published: February 24, 2024

A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.

A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.

Journal: Hematology (Amsterdam, Netherlands)

Published: May 03, 2023

Co-occurrence of mucosal leishmaniasis caused by Leishmania infantum and mucosal-associated lymphoid tissue lymphoma.

Co-occurrence of mucosal leishmaniasis caused by Leishmania infantum and mucosal-associated lymphoid tissue lymphoma.

Journal: Travel medicine and infectious disease

Published: August 16, 2022

Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.

Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 06, 2022

Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.

Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.

Journal: Bone marrow transplantation

Published: October 29, 2021

ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells.

ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 15, 2021

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.

Journal: Blood

Published: July 29, 2021

Corrigendum to 'Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers': [Annals of Oncology Volume 29, Issue 3, March 2018, Pages 715-723].

Corrigendum to 'Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers': [Annals of Oncology Volume 29, Issue 3, March 2018, Pages 715-723].

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 16, 2021

Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Journal: Future oncology (London, England)

Published: February 02, 2021

A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: October 27, 2020

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.

Journal: Blood advances

Published: July 29, 2020

Showing 1-12 of 126

Last Updated: 09/26/2026